|
|
Poll Results
Which insulins do you or your child use?
Vote for all that apply
Short acting insulins
NovoLog/Novorapid
33%
304
Humalog
17%
159
Regular/Actrapid/Velosulin
1%
9
Apidra
1%
17
Other short acting insulin
1%
2
Long acting insulins
Lantus
31%
280
Levemir
4%
39
NPH/Isophane/Insulatard
6%
62
Lente
1%
2
Ultralente
1%
2
Other long acting insulin
1%
6
Other
Premixed (70/30, etc.)
1%
12
Other insulin
1%
5
Don't use insulin
1%
2
Total votes: 901
Which insulins do you or your child use?
Poll dates: January 21 - 28, 2007
Total Votes: 901Insulin users today have a great variety of products from which to choose. In the past few years, two fast-acting analogs (NovoLog and Humalog) and one long-acting analog (Lantus) have been introduced and have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to just one percent. NPH use has dropped too, from 32% in 2000 to just 8% in 2006.
This table shows readers' answers to this survey over the past years:
Percentages based on use compared with all responses
Answer Jan 2007 Jan 2006 Jan 2005 Jan 2004 Jan 2003 Jan 2002 Mar 2000 Short acting insulins NovoLog 33% 28% 27% 26% 12% 3% -- Humalog 17% 20% 22% 26% 34% 37% 35% Regular 1% 1% 1% 2% 3% 4% 12% Apidra 1% 1% 1% -- -- -- -- Long acting insulins Lantus 31% 32% 27% 21% 17% 11% -- Levemir 4% 2% 1% -- -- -- -- NPH 6% 8% 14% 16% 22% 28% 32% Lente 1% 1% 1% 1% 1% 3% 4% Ultralente 1% 1% 1% 1% 2% 5% 7% Other Premixed 1% 1% 1% 1% 2% 2% 5% Other insulin 1% 1% 1% 1% 2% 2% 2% Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.
Rapid Acting Insulin Use
The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. Among users of rapid-acting insulin, NovoLog is used by almost two-thirds of our visitors (62%, up from 57% in 2006), while use of Humalog continues to decline (now at 33%, down from 40% in 2006). Apidra, new to the US market in 2006, now has 3% of rapid acting insulin uses. The use of Regular continues to decline.
Data within rapid-acting insulin only illustrating the steady increase in the use of NovoLog
Data for rapid-acting insulin among all responsesLong Acting Insulin Use
As of January 2007, more CWD visitors report using Lantus than any other insulin. This year, almost three-fourths (73%) of people who use long acting insulin report using Lantus, about the same as last year (74%). The use of NPH continues to decline and and now stands at just 16%. Few people use Lente and Ultralente. Levemir, new in 2005, is used by 10%, up from 6% last year. Given the clinical benefits of using Lantus or Levemir over NPH, it's no surprise to see the rapid decline in use of NPH. (See our page about Care Suggestions for citations to studies about NPH.)
Data for long-acting insulin only showing the continuing decline in the use of NPH insulin
Data for long-acting insulin among all responses[Download an Excel spreadsheet with the data and graphs from this poll]
|
|
|||
Last Updated: Sunday February 04, 2007 11:36:05
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, Privacy Policy, and Safe Harbor Policy.
© Children with Diabetes, Inc. 1995-2013. Comments and Feedback.